newsfilter
← Latest News
Business Wire·

Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company's OMS527 Program to Treat Cocaine Use Disorder

– Successful Completion of Animal Drug Interaction Studies Triggers Funding for Phase 1b Clinical Trial in Patients with CUD – Omeros Corporation (NASDAQ:OMER) today announced that it has received a funding commitment